BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth improvements in children. The company also strengthened its leadership by adding Dr. Robert Plenge, a top research executive from Bristol Myers Squibb, to its board. BioMarin has submitted a supplemental FDA application for VOXZOGO, aiming for approval and launch in 2027 as the first targeted therapy for this rare genetic condition.
BioMarin Pharmaceutical is the story's subject, here is Pluang's market snapshot as of Sep 16, 2026 00:52 WIB: Among 91 priced Health-sector US stocks on Pluang, 28 rose and 63 fell today. Notable movers include BNGO at USD 1.71 with a 28.57% increase, ASND at USD 231.16 down 12.74%, and ILMN at USD 225.13 up 8.13%.
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
Comcast announced a strategic restructuring to separate its connectivity and technology division from its media operations, including NBCUniversal and Sky. UBS raised Comcast's price target to $27, suggesting a 10% upside from current prices. The com...
Vera Bradley reported a strong quarter with earnings per share of $0.11, beating analyst expectations of a $0.08 loss. Revenue rose 1.1% year-over-year to $71.65 million, supported by an 8.0% increase in direct-to-consumer sales. The company’s ongoin...
